In­cyte keeps rolling on top­i­cal cream for JAK in­hibitor, pass­ing two PhI­II tests in vi­tili­go

As In­cyte pre­pares to po­ten­tial­ly hit the mar­ket with a top­i­cal for­mu­la­tion of its cash cow rux­oli­tinib in atopic der­mati­tis, the Wilm­ing­ton, DE-based com­pa­ny is beef­ing up its da­ta pack­age for an­oth­er in­di­ca­tion: vi­tili­go.

In­cyte re­leased Phase III re­sults from two of its clin­i­cal vi­tili­go pro­grams Mon­day morn­ing, say­ing both stud­ies met their pri­ma­ry end­points of pa­tients achiev­ing at least 75% im­prove­ment from base­line in repig­men­ta­tion of the face. The da­ta will like­ly lead In­cyte to ask for ap­proval in both the US and Eu­rope for those old­er than 12 be­fore the end of the year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.